Background The virus neutralization assay is a principal method to assess the efficacy of
antibodies in blocking viral entry. Due to biosafety handling requirements of viruses …

The globalization of the world's economies, accompanied by increasing international travel,
changing climates, altered human behaviour and demographics is leading to the …

Abstract Background The recent Ebola outbreak in West Africa led to the use of a variety of
different platform technologies for assaying antibodies because of the difficulties of handling …

Recent decades have witnessed an unprecedented rise in the outbreak occurrence of
infectious and primarily zoonotic viruses. Contributing factors to this phenomenon include …

Previously unidentified viruses, such as Middle East respiratory syndrome coronavirus,
continue to emerge and threaten populations, while powerful new techniques have …

Pseudotype viruses (PVs) are chimeric, replication-deficient virions that mimic wild-type
virus entry mechanisms and can be safely employed in neutralisation assays, bypassing the …

Ebola virus (EBOV), classified as a category A agent by the CDC and NIH, requires BSL-4
containment and induces high morbidity and mortality in humans. The 2013–2015 epidemic …

Pseudotype neutralization assays are powerful tools to study functional antibody responses
against viruses in low biosafety laboratories. However, protocols described in the literature …

Pseudoviruses are useful surrogates for highly pathogenic viruses because of their safety,
genetic stability, and scalability for screening assays. Many different pseudovirus platforms …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …